Abstract Number: 1267 • ACR Convergence 2020
Perceived Stress During the COVID-19 Pandemic Independently Associates with Worse Patient-Reported Outcomes in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Causes and risk factors for variations in SLE disease activity and symptom severity are incompletely understood. Prior studies suggest a link between stressful life…Abstract Number: 1283 • ACR Convergence 2020
Factors Affecting Mortality of Systemic Lupus Erythematosus Patients in Spain in the 21st Century: Data from the RELESSER Registry
Background/Purpose: The mortality in Systemic Lupus Erythematosus (SLE) varies largely across different countries most probably due to social, healthcare and ethnic differences.To analyze the causes…Abstract Number: 1299 • ACR Convergence 2020
Longitudinal Patterns of Anxiety Symptomology Among Patients with Systemic Lupus Erythematosus (SLE) Remain Stable over Time and Do Not Associate with SLE Disease Activity
Background/Purpose: Almost 40% of patients with SLE have comorbid mental health conditions.1 Though depression is most commonly reported (24% to 30%), many SLE patients also…Abstract Number: 1510 • ACR Convergence 2020
Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events
Background/Purpose: Platelets have a well-defined role in arterial thrombosis, and platelet-bound complement activation products (PC4d) correlate with vascular thromboses in patients with Systemic Lupus Erythematosus…Abstract Number: 1669 • ACR Convergence 2020
Genetics of Age at Diagnosis in Systemic Lupus Erythematosus
Background/Purpose: Genome wide association studies (GWAS) have identified >90 SNPs associated with systemic lupus erythematosus (SLE) risk. However, there may be additional loci impacting the…Abstract Number: 1768 • ACR Convergence 2020
The Importance of Pregnancy Planning in Lupus Pregnancies
Background/Purpose: Given the clinical importance of the pre-conception period in lupus pregnancy management and because pregnancy planning can be potentially improved, this study explores the…Abstract Number: 1798 • ACR Convergence 2020
IgE Anti-dsDNA Antibodies in Systemic Lupus Erythematosus Are Associated with Higher Disease Activity at the Baseline and in Longterm Follow-up
Background/Purpose: Recent reports indicate that autoreactive anti-dsDNA IgE autoantibodies and IgE immune complexes and can activate innate and adaptive immunity leading to amplification of lupus…Abstract Number: 1816 • ACR Convergence 2020
Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis
Background/Purpose: Tubulointerstitial disease (TID), defined as tubulointerstitial inflammation (TII) or interstitial fibrosis/tubular atrophy (IFTA), is associated with progression to end stage renal disease (ESRD) in…Abstract Number: 1832 • ACR Convergence 2020
Barriers to Medication Adherence and Degree of Nonadherence in a Systemic Lupus Erythematosus Outpatient Population
Background/Purpose: It has been reported that 50% to 75% of patients with SLE do not adhere to their medications. However, the reasons for nonadherence are not clear.…Abstract Number: 1980 • ACR Convergence 2020
Understanding the Relationship Between Illness Perceptions and Self-Efficacy Among Latin Americans with SLE Through the Hablemos De Lupus Facebook Page
Background/Purpose: SLE disproportionately strikes Latinos, who are also at high risk for poor outcomes. Self-efficacy (SE) to manage chronic disease correlates with outcomes through self-management…Abstract Number: 0002 • ACR Convergence 2020
Hydroxychloroquine and Chloroquine and Hospitalizations for Viral Infection in the Pre-COVID-19 Era
Background/Purpose: Chloroquine (CQ) and hydroxychloroquine (HCQ) have been shown to have antiviral properties and were considered as potential therapeutic options amid the COVID-19 pandemic. The…Abstract Number: 0252 • ACR Convergence 2020
Corticosteroid and Opioid Use Remain High in Systemic Lupus Erythematosus Patients Receiving Biologic Therapy: A Retrospective Claims Database Analysis
Background/Purpose: SLE is managed by variable combinations of five drug classes: antimalarials, biologics, corticosteroids, non-steroidal anti-inflammatory agents, and immunosuppressants. Opioids are commonly prescribed to SLE…Abstract Number: 0269 • ACR Convergence 2020
Systemic Lupus Erythematosus with Libman-Sacks Endocarditis Increases Inpatient Mortality
Background/Purpose: Libman-Sacks endocarditis characterized by thrombotic and/or non-infective sterile inflammatory vegetations are common in Systemic Lupus Erythematosus (SLE) and associated with increased morbidity. These vegetations…Abstract Number: 0286 • ACR Convergence 2020
An SLE-linked ITGAM Gene Variant Changes Mac-1 Structure, Signaling, and Surface Expression and Enhances IFNg Production and Antigen Presentation by B Cells
Background/Purpose: SLE is a chronic and debilitating disease; in the USA with an estimated incidence of 3-10 per 100,000 people and currently affecting an estimated…Abstract Number: 0303 • ACR Convergence 2020
SLE Patients Stratify into Distinct Clusters Based on Their Peripheral Blood Immunologic Phenotype During Acute Flare
Background/Purpose: SLE is a chronic autoimmune disease in which periods of quiescence are interspersed with acute flares of disease activity that produce much of the…
- « Previous Page
- 1
- …
- 148
- 149
- 150
- 151
- 152
- …
- 181
- Next Page »
